| 7.97 -0.34 (-4.09%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.52 | 1-year : | 11.97 |
| Resists | First : | 9.01 | Second : | 10.25 |
| Pivot price | 8.18  |
|||
| Supports | First : | 7.01 | Second : | 5.83 |
| MAs | MA(5) : | 7.91 |
MA(20) : | 8.52 |
| MA(100) : | 8.72  |
MA(250) : | 6.28 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 34.1 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 11.98 | Low : | 3.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CSBR ] has closed above bottom band by 38.9%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.86 - 8.91 | 8.91 - 8.94 |
| Low: | 7.79 - 7.84 | 7.84 - 7.87 |
| Close: | 7.9 - 7.97 | 7.97 - 8.03 |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Fri, 18 Apr 2025
Press Release Distribution & PR Platform - ACCESS Newswire
Sun, 13 Apr 2025
Champions Oncology's (NASDAQ:CSBR) investors will be pleased with their respectable 47% return over the last year - Yahoo
Sat, 05 Apr 2025
Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding - simplywall.st
Mon, 17 Mar 2025
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView
Wed, 12 Mar 2025
Champions Oncology, Inc. (NASDAQ:CSBR) Q3 2025 Earnings Call Transcript - Insider Monkey
Tue, 11 Mar 2025
Champions Oncology Reports Record Quarterly Revenue and Net Income - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 25.8 (%) |
| Held by Institutions | 47.7 (%) |
| Shares Short | 124 (K) |
| Shares Short P.Month | 99 (K) |
| EPS | 0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 10.9 % |
| Operating Margin | 26.3 % |
| Return on Assets (ttm) | 14.6 % |
| Return on Equity (ttm) | 376.8 % |
| Qtrly Rev. Growth | 41.7 % |
| Gross Profit (p.s.) | 2.18 |
| Sales Per Share | 4.23 |
| EBITDA (p.s.) | 0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 17.71 |
| PEG Ratio | 0 |
| Price to Book value | 19.92 |
| Price to Sales | 1.88 |
| Price to Cash Flow | -84.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|